Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid

Authors

  • Päivi Leisti Department of Dermatology, Research Unit of Clinical Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
  • Anna Pankakoski Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Jari Jokelainen Infrastructure for Population Studies, University of Oulu, Oulu, Finland
  • Laura Huilaja Department of Dermatology, Research Unit of Clinical Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
  • Jaana Panelius Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Kaisa Tasanen 1Department of Dermatology, Research Unit of Clinical Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
  • Outi Varpuluoma 1Department of Dermatology, Research Unit of Clinical Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

DOI:

https://doi.org/10.2340/actadv.v104.40645

Keywords:

Bullous pemphigoid, epidemiology, gliptin, dipeptidyl-4 peptidase, mortality

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019; 10: 1238.

https://doi.org/10.3389/fimmu.2019.01238 DOI: https://doi.org/10.3389/fimmu.2019.01238

Leisti P, Pankakoski A, Jokelainen J, Varpuluoma O, Huilaja L, Panelius J, et al. Accurate diagnosis of bullous pemphigoid requires multiple health care visits. Front Immunol 2023: 27: 14: 1281302.

https://doi.org/10.3389/fimmu.2023.1281302 DOI: https://doi.org/10.3389/fimmu.2023.1281302

Försti A, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid - more than skin deep? Exp Dermatol 2017; 26: 1228-1234.

https://doi.org/10.1111/exd.13401 DOI: https://doi.org/10.1111/exd.13401

Nieto-Benito LM, Bergón-Sendín M, Pulido-Pérez A, Rosell-Díaz ÁM, Parra-Blanco V, Suárez-Fernández R. Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: a single-centre retrospective study. Exp Dermatol 2021; 30: 1345-1351.

https://doi.org/10.1111/exd.14387 DOI: https://doi.org/10.1111/exd.14387

Kinyó Á, Hanyecz A, Lengyel Z, Várszegi D, Oláh P, Gyömörei C, et al. Clinical, laboratory and histological features of dipeptidyl peptidase-4 inhibitor related noninflammatory bullous pemphigoid. J Clin Med 2021; 10: 1916.

https://doi.org/10.3390/jcm10091916 DOI: https://doi.org/10.3390/jcm10091916

Horikawa H, Kurihara Y, Funakoshi T, Umegaki-Arao N, Takahashi H, Kubo A, et al. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol 2018; 6: 1462-1463.

https://doi.org/10.1111/bjd.16479 DOI: https://doi.org/10.1111/bjd.16479

Chen X, Zhang Y, Luo Z, Wu Y, Niu T, Zheng J, et al. Prognostic factors for mortality in bullous pemphigoid: a systematic review and meta-analysis. PLoS One 2022. 15; 17: e0264705.

https://doi.org/10.1371/journal.pone.0264705 DOI: https://doi.org/10.1371/journal.pone.0264705

Mannucci E, Nreu B, Montereggi C, Ragghianti B, Gallo M, Giaccari A, et al. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2021; 22; 31: 2745-2755.

https://doi.org/10.1016/j.numecd.2021.06.002 DOI: https://doi.org/10.1016/j.numecd.2021.06.002

Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021; 10: CD013650.

https://doi.org/10.1002/14651858.CD013650.pub2 DOI: https://doi.org/10.1002/14651858.CD013650.pub2

Downloads

Published

2024-09-04

How to Cite

Leisti, P., Pankakoski, A., Jokelainen, J., Huilaja, L., Panelius, J., Tasanen, K., & Varpuluoma, O. (2024). Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid. Acta Dermato-Venereologica, 104, adv40645. https://doi.org/10.2340/actadv.v104.40645

Issue

Vol. 104 (2024)

Section

Short Communication

Categories

License

Copyright (c) 2024 Päivi Leisti, Anna Pankakoski, Jari Jokelainen, Laura Huilaja, Jaana Panelius, Kaisa Tasanen, Outi Varpuluoma

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC